Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.23259PMID 18205185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Anastrozole on Bone-Mineral Density

  2008cited by this paper
• Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

  2007cited by this paper
• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  2007cited by this paper
• Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

  2007influential reference
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.

  2006cited by this paper
• Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.

  2006cited by this paper
• Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

  2006cited by this paper
• A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

  2006cited by this paper
• Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Long-term effects of aromatase inhibitors on bone.

  2005cited by this paper
• ATAC trial update.

  2005cited by this paper
• Predictive Value of BMD for Hip and Other Fractures

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations.

  2005cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

  2004cited by this paper
• Bone mineral density thresholds for pharmacological intervention to prevent fractures.

  2004cited by this paper
• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  2003influential reference
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003cited by this paper
• Prevention and management of osteoporosis.

  2003cited by this paper
• Sex steroids and the construction and conservation of the adult skeleton.

  2002cited by this paper
• Aromatase and its inhibitors: significance for breast cancer therapy.

  2002cited by this paper
• Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

  1996cited by this paper
• 96153999 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

  1996cited by this paper
• Prevention and management of osteoporosis.

  1995cited by this paper

• Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis

  2026cites this paper
• Effects of Anticancer Therapy on Osteoporosis in Breast Cancer Patients: A Nationwide Study Using Data from the National Health Insurance Service-National Health Information Database

  2025cites this paper
• Hip fracture and cancer: descriptive epidemiological study demonstrating a paradigm shift in common orthopedic trauma

  2025cites this paper
• Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

  2025cites this paper
• Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials

  2024cites this paper
• Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.

  2024cites this paper
• Bone health in breast cancer.

  2023cites this paper
• A Recent Review of the Management of Postmenopausal Symptoms in Breast Cancer Survivors

  2023cites this paper
• Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials

  2022influential citation
• The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data

  2022cites this paper
• Evaluation of knowledge and attitudes of cancer patients on vitamin and mineral supplements

  2021cites this paper
• Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease

  2021cites this paper
• An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer

  2021cites this paper
• Osteoporosis Management with Focus on Spine

  2021cites this paper
• Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

  2021cites this paper
• Breast cancer therapy and bone

  2021cites this paper
• Knowledge and Attitudes of Cancer Patients towards Vitamin and Mineral Supplements: A Comprehensive Evaluation

  2021cites this paper
• Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.

  2021cites this paper
• Manifestations Ostéoarticulaires Associées à l’Utilisation des Antiaromatases dans le Traitement du Cancer du Sein au CHU Hassan II de Fès

  2020cites this paper
• The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease

  2020cites this paper
• Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions

  2020cites this paper
• The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part II: Metastatic Disease

  2020cites this paper
• Therapeutic Dimensions of Bisphosphonates: A Clinical Update

  2020cites this paper
• Bone marrow osteoprogenitors are depleted whereas osteoblasts are expanded independent of the osteogenic vasculature in response to zoledronic acid

  2019cites this paper
• Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

  2019cites this paper
• French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

  2019cites this paper
• Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein

  2019cites this paper
• Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.

  2019cites this paper
• Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  2019cites this paper
• Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer.

  2019cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Prevention and Treatment of Skeletal Complications

  2019cites this paper
• Bone health care in women with breast cancer

  2019cites this paper
• Prevention and treatment of osteoporosis in postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors

  2019cites this paper
• Changes in Bone Mineral Density in Women With Breast Cancer: A Prospective Cohort Study

  2019cites this paper
• The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

  2019cites this paper
• Absolute Clinical Radiation Oncology Review

  2019cites this paper
• Breast Cancer

  2019cites this paper
• Breast Cancer, Including Brief Discussion of Male Breast Cancer

  2018cites this paper
• Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment

  2018influential citation
• Bone health during endocrine therapy for cancer.

  2018cites this paper
• Bone Health in Patients with Breast Cancer

  2018cites this paper
• Management of Menopause in the Breast Cancer Patient

  2018cites this paper
• A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

  2018cites this paper
• Breast tumor stroma: A driving force in the development of resistance to therapies

  2017cites this paper
• Osteoporosis management in patients with breast cancer: EMAS position statement.

  2017cites this paper
• An investigation of the relationship between the components of tumour microenvironment, signal transduction pathways and outcome in breast cancer

  2017cites this paper
• Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment.

  2017cites this paper
• Evaluation and management of skeletal disease in cancer care.

  2017cites this paper
• Skeletal health in breast cancer survivors.

  2017cites this paper
• Stratified medicine: methods for evaluation of predictive biomarkers

  2017cites this paper
• Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience

  2017cites this paper
• Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis

  2016cites this paper
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

  2016cites this paper
• Efficacy of Adjuvant Zolodronic Acid in Post Menopausal Women with Early Breast Cancer Receiving Adjuvant Aromatas Inhibitor on Improving Bone Health

  2016cites this paper
• The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution

  2016cites this paper
• Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole

  2016cites this paper
• Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.

  2016cites this paper
• A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.

  2016cites this paper
• Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.

  2016cites this paper
• Calcitonin Receptor AluI (rs1801197) and Taq1 Calcitonin Genes Polymorphism in 45-and Over 45-year-old Women and their Association with Bone Density

  2016cites this paper
• Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole

  2016cites this paper
• Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

  2015cites this paper
• Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

  2015cites this paper
• Issues associated with aromatase inhibitor–associated musculoskeletal symptoms in breast cancer

  2015cites this paper
• Prevention and treatment of bone fragility in cancer patient.

  2015cites this paper
• Considerations regarding adherence of anti-osteoporosis therapy

  2015cites this paper
• Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

  2015cites this paper
• Sp1 binding site polymorphism of a collagen gene (rs 1800012) in women aged 45 and over and its association with bone density.

  2015cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• Hormonal therapy in oncology: a primer for the radiologist.

  2015cites this paper
• The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany

  2015cites this paper
• Studying the effect of adding zoledronic acid to anastrozole as neoadjuvant hormonal therapy in locally-advanced elderly breast cancer patients

  2014cites this paper
• The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis

  2014influential citation
• Role of bisphosphonates in postmenopausal women with breast cancer.

  2014cites this paper
• Investigating the effects of aromatase inhibitors on the musculoskeletal system

  2014cites this paper
• Bone Metastases

  2014cites this paper
• Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

  2014cites this paper
• Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

  2014cites this paper
• Systemic Therapy of Bone Metastases

  2014cites this paper
• Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.

  2014cites this paper
• Bisphosphonates in the adjuvant treatment of breast cancer.

  2013cites this paper
• Aromatase Inhibitors: How much it Bites the Bone?

  2013cites this paper
• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

  2013influential citation
• Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

  2013cites this paper
• Osteoporosis secundaria. Tratamiento actualizado

  2013cites this paper
• Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial

  2013cites this paper
• Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis

  2013cites this paper
• Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort

  2013cites this paper
• Secondary causes of osteoporosis.

  2013cites this paper
• What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?

  2013cites this paper
• Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

  2013cites this paper
• Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.

  2013cites this paper
• NCCN Task Force Report: Bone Health In Cancer Care.

  2013cites this paper
• Impact of denosumab on bone mass in cancer patients

  2013cites this paper
• Pertuzumab: new hope for patients with HER2-positive breast cancer.

  2013cites this paper
• Task Force Report : Bone Health in Cancer Care

  2013cites this paper
• Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.

  2013cites this paper
• Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.

  2012cites this paper
• Final 5‐year results of Z‐FAST trial

  2012cites this paper